| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/17/2023 | -56.24% | UBS | $12 → $3.75 | Downgrades | Neutral → Sell |
| 08/14/2023 | -94.17% | Credit Suisse | $2.5 → $0.5 | Maintains | Neutral |
| 08/11/2023 | — | Jefferies | Downgrades | Buy → Hold | |
| 08/11/2023 | -90.67% | Citigroup | $4 → $0.8 | Downgrades | Buy → Neutral |
| 05/16/2023 | -88.33% | Piper Sandler | $0.5 → $1 | Maintains | Underweight |
| 05/12/2023 | -70.83% | Credit Suisse | → $2.5 | Reiterates | Neutral → Neutral |
| 01/06/2023 | -85.41% | UBS | $12 → $1.25 | Downgrades | Buy → Neutral |
| 01/05/2023 | — | Wolfe Research | Downgrades | Outperform → Peer Perform | |
| 12/13/2022 | -82.5% | B of A Securities | → $1.5 | Reinstates | → Underperform |
| 11/16/2022 | -41.66% | Citigroup | $7 → $5 | Maintains | Buy |
| 11/10/2022 | -64.99% | Cowen & Co. | $10 → $3 | Downgrades | Outperform → Market Perform |
| 11/10/2022 | — | Raymond James | Downgrades | Outperform → Market Perform | |
| 10/27/2022 | -41.66% | Credit Suisse | $10 → $5 | Downgrades | Outperform → Neutral |
| 09/07/2022 | -18.32% | Truist Securities | → $7 | Initiates Coverage On | → Hold |
| 08/10/2022 | -53.33% | Piper Sandler | $4 → $4 | Maintains | Underweight |
| 06/24/2022 | -6.65% | Raymond James | → $8 | Initiates Coverage On | → Outperform |
| 06/15/2022 | -29.99% | B of A Securities | $8 → $6 | Downgrades | Buy → Neutral |
| 05/11/2022 | 16.69% | Credit Suisse | $13 → $10 | Maintains | Outperform |
| 05/11/2022 | -53.33% | Piper Sandler | $5 → $4 | Maintains | Underweight |
| 05/10/2022 | -6.65% | Citigroup | $10 → $8 | Maintains | Buy |
| 05/03/2022 | -6.65% | B of A Securities | → $8 | Initiates Coverage On | → Buy |
| 04/20/2022 | 75.03% | UBS | → $15 | Initiates Coverage On | → Buy |
| 04/06/2022 | -41.66% | Piper Sandler | $8.5 → $5 | Downgrades | Neutral → Underweight |
| 03/16/2022 | 51.69% | Credit Suisse | $15 → $13 | Maintains | Outperform |
| 11/10/2021 | 51.69% | Piper Sandler | $11 → $13 | Maintains | Neutral |
| 10/20/2021 | 98.37% | Jefferies | → $17 | Initiates Coverage On | → Buy |
| 10/19/2021 | 28.35% | Piper Sandler | → $11 | Initiates Coverage On | → Neutral |
| 10/01/2021 | 121.7% | Wolfe Research | → $19 | Initiates Coverage On | → Outperform |
| 09/21/2021 | 133.37% | Citigroup | → $20 | Initiates Coverage On | → Buy |
| 09/10/2021 | 110.04% | Cowen & Co. | → $18 | Initiates Coverage On | → Outperform |
| 08/02/2021 | 110.04% | Credit Suisse | → $18 | Initiates Coverage On | → Outperform |
What is the target price for Cano Health (CANO)?
The latest price target for Cano Health (NYSE: CANO) was reported by UBS on November 17, 2023. The analyst firm set a price target for $3.75 expecting CANO to fall to within 12 months (a possible -56.24% downside). 9 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Cano Health (CANO)?
The latest analyst rating for Cano Health (NYSE: CANO) was provided by UBS, and Cano Health downgraded their sell rating.
When is the next analyst rating going to be posted or updated for Cano Health (CANO)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cano Health, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cano Health was filed on November 17, 2023 so you should expect the next rating to be made available sometime around November 17, 2024.
Is the Analyst Rating Cano Health (CANO) correct?
While ratings are subjective and will change, the latest Cano Health (CANO) rating was a downgraded with a price target of $12.00 to $3.75. The current price Cano Health (CANO) is trading at is $8.57, which is out of the analyst's predicted range.
